RE:RE:RE:Dr. Black article on Phase 2 Trial of Atezolizumabenriquesuave wrote: Adstiladrin 12 months CR is about 24%. We are beating them badly. ( 46% of the 51% who are CR remain so at 12 months, so it's not 46% but 23.5%). . We may end up with double that, and much simpler manufacturing and less side effects, as well as less treatments.
Well, it's settled then. If I am one of the FDA experts that said TLT data is good enough to be fast-tracked and to come back and show me phase 2 data for 25 patients that is in the same vicinity - with emphasis on safety and efficacy- we should already be there? What grounds would I have now to say NO? Only unknown is if there were other things that came up that we have no visibility to which pushed the data submission out. Hopefully, we'll know very soon.